KIDNEY CANCER DRUGS MARKET ANALYSIS

Name: Kidney Cancer Drugs Market News
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy

Kidney Cancer Drugs Market, By Therapy: Targeted Therapy, Immunotherapy, and Chemotherapy, By Pharmacological Class: Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines, and Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies , and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In December 2022, Exelixis, Inc., a biotechnology company specializing in oncology, unveiled the commencement of the STELLAR-304 trial. This phase-3 pivotal study aims to assess the efficacy of zanzalintinib combined with nivolumab compared to sunitinib in patients with advanced non-clear cell kidney cancer.
In October 2022, Health Canada granted the approval for KEYTRUDA (pembrolizumab) as a standalone treatment for adults with renal cell carcinoma (RCC) in the adjuvant setting. This approval applies to individuals at intermediate-high or high risk of recurrence post-nephrectomy, or post-nephrectomy along with resection of metastatic lesions.
In February 2022, Eisai Co., Ltd. A human health care company. and Merck & Co., Inc., global health care company Rahway, NJ, USA, announced the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) for the combination therapy of LENVIMA by Eisai and KEYTRUDA by Merck & Co., Inc. This approval is for the treatment of radically unresectable or metastatic renal cell carcinoma, the most prevalent form of kidney cancer.